Physician profile
Cortney E Farmer
NPI 1174987069
$2,915.64
in general payments reported to CMS, 2019-2025
28 companies · $181 in 2025
The $181 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $222 · 2020: $216 · 2021: $698 · 2022: $661 · 2023: $474 · 2024: $464 · 2025: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,118.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $811.04 | 2020-2025 | |
| Novo Nordisk INC | $657.09 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $241.88 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $163.93 | 2020-2025 | Breztri, Farxiga |
| Novartis Pharmaceuticals Corporation | $129.48 | 2019-2023 | |
| Amarin Pharma, INC. | $94.26 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $80.39 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.62 | 2021-2025 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $66.54 | 2022 | |
| Allergan, INC. | $61.82 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $56.95 | 2022-2024 | Eliquis, Camzyos |
| Amgen INC. | $56.26 | 2021-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $45.67 | 2019-2025 | |
| Glaxosmithkline, LLC. | $44.84 | 2021-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.52 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $41.63 | 2023-2025 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $33.92 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.99 | 2021 | |
| Horizon Therapeutics Plc | $25.00 | 2020 | |
| Dexcom, INC. | $22.88 | 2024 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $22.26 | 2019 | |
| Axsome Therapeutics, INC. | $21.04 | 2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $20.96 | 2024 | Voquezna |
| Astellas Pharma US INC | $18.80 | 2024 | Veozah |
| Sunovion Pharmaceuticals INC. | $14.69 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $14.35 | 2021 | |
| Circassia INC. | $12.45 | 2019 | |
| Supernus Pharmaceuticals, INC. | $11.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cortney Farmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.